Herbert Conrad Buys 26,000 Shares of Celldex Therapeutics
Insider Herbert Conrad acquired 26,000 shares of Celldex Therapeutics, signaling confidence in the company's future.
Key Points
- Herbert Conrad bought 26,000 shares of Celldex Therapeutics on June 25, 2026, showing insider confidence.
- Celldex shares traded at $37.44 on Tuesday, with a market cap of about $2.77 billion and a 52-week high of $35.79.
- Analysts maintain a strong buy consensus with a target mean price of $57.53, backed by recent insider buying activity.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Herbert Conrad, an insider, purchased 26,000 shares of Celldex Therapeutics, Inc. (NasdaqCM: CLDX) on June 25, 2026. This transaction was not part of a pre-planned trading program, suggesting confidence in the company's prospects.
Insider Buying and Selling at Celldex Therapeutics, Inc.
On June 25, 2026, several insiders, including Herbert Conrad, purchased shares of Celldex Therapeutics. Conrad acquired 26,000 shares, while other executives such as Ronald Pepin, Samuel Bates Martin, and Denice Torres also made significant purchases. These transactions reflect a positive sentiment among the company's leadership.
Celldex Therapeutics, Inc. Stock Down 4.3%
Shares of Celldex Therapeutics traded around $37.44 on Tuesday. The company, with a market capitalization of approximately $2.77 billion, operates in the biotechnology industry, focusing on therapeutic antibodies. Its stock has a 52-week range between $19.52 and $35.79, with a beta of 0.93, indicating moderate volatility. The company's 50-day moving average stands at $32.10, while the 200-day moving average is $28.27.
$CLDX stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analysts have maintained a positive outlook on Celldex Therapeutics. On June 15, 2026, HC Wainwright & Co. reiterated a buy rating with a $42.00 price target. UBS and Wells Fargo also maintained buy ratings with targets of $45.00 and $54.00, respectively, earlier this year. The consensus among 15 analysts is a strong buy, with a target mean price of $57.53.
About Celldex Therapeutics
Celldex Therapeutics, Inc. is a biopharmaceutical company based in Hampton, New Jersey. It develops therapeutic antibodies for severe inflammatory, allergic, autoimmune, and other diseases. The company is known for its drug candidates like Barzolvolimab and CDX-622, which target mast cell-mediated diseases. Led by CEO Anthony S. Marucci, Celldex employs about 198 people.
Bottom Line
Herbert Conrad's recent purchase of Celldex Therapeutics shares underscores a notable insider confidence in the company's future. While insider transactions can offer insights, it's essential to remember that these filings reflect past actions and may not indicate current positions. Investors often track such activity for potential signals about a company's outlook.
Get Celldex Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CLDX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.